featured
Improved Survival of HER2-Positive MBC Patients With Newly Diagnosed vs Recurrent Disease Undergoing First-Line Trastuzumab-Based Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patterns of Care and Clinical Outcomes of HER2-Positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-Line Trastuzumab-Based Therapy: A Multicenter Retrospective Cohort Study
Clin. Breast Cancer 2017 Apr 11;[EPub Ahead of Print], M Lambertini, AR Ferreira, A Di Meglio, F Poggio, F Puglisi, F Sottotetti, F Montemurro, E Poletto, A Bernardo, E Risi, C Dellepiane, V Sini, G Minuti, D Grasso, S Fancelli, L Del MastroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.